Matthias Geberth

1.1k total citations
24 papers, 730 citations indexed

About

Matthias Geberth is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Matthias Geberth has authored 24 papers receiving a total of 730 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Matthias Geberth's work include Cancer Treatment and Pharmacology (14 papers), Advanced Breast Cancer Therapies (13 papers) and Breast Cancer Treatment Studies (11 papers). Matthias Geberth is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Advanced Breast Cancer Therapies (13 papers) and Breast Cancer Treatment Studies (11 papers). Matthias Geberth collaborates with scholars based in Germany, United States and Austria. Matthias Geberth's co-authors include W. Jonat, Martin Schumacher, M. Kaufmann, M. Namer, M K Palmer, R.W. Blamey, I. Fogelman, J. Cuzick, Alan L. Stewart and B. Lisboa and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Matthias Geberth

23 papers receiving 703 citations

Peers

Countries citing papers authored by Matthias Geberth

Since Specialization

Citations

This map shows the geographic impact of Matthias Geberth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Geberth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Geberth more than expected).

Fields of papers citing papers by Matthias Geberth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Geberth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Geberth. The network helps show where Matthias Geberth may publish in the future.

Co-authorship network of co-authors of Matthias Geberth

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Geberth. A scholar is included among the top collaborators of Matthias Geberth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Geberth. Matthias Geberth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Use of primary and secondary pegfilgrastim prophylaxis for reducing incidence of neutropenia: Findings from a large study in German clinical practice (PROTECT) 2018 ·Annals of Oncology ·Christian M. Kurbacher, Mona Wanda Schmidt, Matthias Geberth, Burkhard Otremba, (unknown), (unknown)	1
2	First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. 2016 ·PubMed ·Andreas Schneeweiß, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth, (unknown), (unknown), Claudia Schumacher, (unknown), Claudia Kiewitz, (unknown), Marcus Schmidt	10
3	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 2014 ·Annals of Oncology ·Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, (unknown), Mona El-Hashimy, T Taran, Howard A. Burris	93
4	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 2013 ·JNCI Journal of the National Cancer Institute ·Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Howard A. Burris, Martine Piccart, Gabriel N. Hortobágyi, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Matthias Geberth, Lowell L. Hart, Peyman Hadji, Mona El-Hashimy, (unknown), Tetiana Taran, Tarek Sahmoud, David Lebwohl, Mario Campone, Kathleen I. Pritchard	77
5	Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 2013 ·Breast Cancer Research and Treatment ·J. Thaddeus Beck, Gabriel N. Hortobágyi, Mario Campone, Fabienne Lebrun, Ines Deleu, Hope S. Rugo, Barbara Pistilli, Norikazu Masuda, Lowell L. Hart, Bohuslav Melichar, Shaker R. Dakhil, Matthias Geberth, (unknown), Daniel Y.C. Heng, Thomas Brechenmacher, Mona El-Hashimy, (unknown), François Ringeisen, Martine Piccart	75
6	Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors 2013 ·Oncology Research and Treatment ·Viktor Grünwald, Steffen Weikert, Marianne Pavel, Dieter Hörsch, Diana Lüftner, Wolfgang Janni, Matthias Geberth, Matthias M. Weber	32
7	Clinical management and resolution of stomatitis in BOLERO-2. 2013 ·Journal of Clinical Oncology ·Alejandra Perez, Hope S. Rugo, José Baselga, Lowell L. Hart, Kathleen I. Pritchard, Francis P. Arena, Janice F. Eakle, Matthias Geberth, Gabriel N. Hortobágyi, Tibor Csőszi, Michael Gnant, E. Chouinard, Shinzaburo Noguchi, Vichien Srimuninnimit, Puttisak Puttawibul, Daniel Yick Chin Heng, Ashok Panneerselvam, Tanya Taran, Tarek Sahmoud, Howard A. Burris	3
8	Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study. 2012 ·Journal of Clinical Oncology ·Iris Schrader, (unknown), Andreas Schneeweiß, Matthias Geberth, (unknown), Claudia Schumacher, (unknown), Winfried Schoenegg, (unknown), (unknown), Marcus Schmidt, Bahriye Aktas	0
9	Efficacy and Safety of First-Line Bevacizumab (BEV) Combined with Paclitaxel (PAC) According to Age: Subpopulation Analysis of a Large, Multicenter, Non-Interventional Study in Patients (Pts) with HER2-Negative Metastatic Breast Cancer (MBC). 2009 ·Cancer Research ·Matthias Geberth, (unknown), Peter Klare, Andreas Schneeweiß, Cassie Schumacher, (unknown), Hans Tesch, (unknown), (unknown), Oleg Gluz, Sherko Küemmel, Dirk Strumberg, (unknown), Marcus Schmidt	2
10	A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer – GABG-IV B-93 2007 ·European Journal of Cancer ·Manfred Kaufmann, Erika Graf, W. Jonat, W. Eiermann, Sabine Vescia, Matthias Geberth, Bettina Conrad, G. Gademann, Ute‐Susann Albert, Sibylle Loibl, Gϋnter von Minckwitz, Martin Schumacher	18
11	CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93) 2006 ·European Journal of Cancer ·Gϋnter von Minckwitz, Erika Graf, Matthias Geberth, W. Eiermann, W. Jonat, Bettina Conrad, (unknown), Bernd Gerber, Sabine Vescia, (unknown), Manfred Kaufmann	28
12	Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy 2004 ·Anti-Cancer Drugs ·Andreas Schneeweiß, (unknown), Hans‐Peter Sinn, Kristina Unnebrink, Christian Rudlowski, Matthias Geberth, (unknown), G. Bastert, (unknown)	18
13	Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93 2004 ·Journal of Clinical Oncology ·M. Kaufmann, Erika Graf, W. Jonat, W. Eiermann, (unknown), Matthias Geberth, Bettina Conrad, G. Gademann, K.-D. Schulz	8
14	455 A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her-2 negative metastatic breast cancer (MBC) 2003 ·European Journal of Cancer Supplements ·F. Lenz, (unknown), Matthias Geberth, G. Bastert, Andreas Schneeweiß	8
15	Phase-II Studie zur Beurteilung der Wirksamkeit und Toxizität der Kombinationschemotherapie mit Taxotere und Gemzar in der First-line-Behandlung beim Her2-negativen und anthracyclinvorbehandelten metastasierten Mammakarzinom 2003 ·Geburtshilfe und Frauenheilkunde ·F. Lenz, Andreas Schneeweiß, (unknown), Matthias Geberth, G. Bastert	1
16	Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study 2002 ·Journal of Clinical Oncology ·W. Jonat, M. Kaufmann, Willi Sauerbrei, R.W. Blamey, J. Cuzick, M. Namer, I. Fogelman, J C de Haes, A. De Matteis, Alan L. Stewart, (unknown), (unknown), M K Palmer, Martin Schumacher, Matthias Geberth, B. Lisboa	246
17	Die palliative Behandlung des metastasierten Mammakarzinoms mit Taxanen: Ein Wirkungsvergleich zwischen Docetaxel und Paclitaxel mittels Matched-Pair-Analyse 2001 ·Zentralblatt für Gynäkologie ·(unknown), F. Lenz, (unknown), Matthias Geberth, R. Goerner, Erich‐Franz Solomayer, (unknown)	1
18	Tandem high-dose chemotherapy in high-risk primary breast cancer: A multivariate analysis and a matched-pair comparison with standard-dose chemotherapy 2001 ·Biology of Blood and Marrow Transplantation ·Andreas Schneeweiß, R. Goerner, Manfred Hensel, (unknown), Hans‐Peter Sinn, (unknown), Gerlinde Egerer, (unknown), Matthias Geberth, Erich Solomayer, Eva‐Maria Grischke, (unknown), Anthony D. Ho, G. Bastert	10
19	Chemotherapy with carboplatin/docetaxel for primary and recurrent epithelial ovarian cancer 2001 ·European Journal of Cancer ·(unknown), (unknown), Matthias Geberth, Andreas Schneeweiß, Jens Huober, Antoine Meyer, G. Bastert	5
20	Management of Heparin-Associated Thrombocytopenia in Pregnancy with Subcutaneous r-Hirudin 2000 ·Gynecologic and Obstetric Investigation ·G. Huhle, Matthias Geberth, Ursula Hoffmann, D. L. Heene, Job Harenberg	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact